Semi-Solid Dosage Contract Manufacturing Market Expansion Outlook: $26.76 Billion in 2029

Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.

What Is the Projected CAGR for the Semi-Solid Dosage Contract Manufacturing Market from 2024 to 2025?
The market size for semi-solid dosage contract manufacturing has seen swift expansion in the recent past. This sector is projected to escalate from a worth of $16.23 billion in 2024 to an estimated $17.97 billion in 2025, translating to a compound annual growth rate (CAGR) of 10.7%. Factors such as an increasing older population, augmentation in worldwide medical expenditure, heightened need for hormone replacement therapies, growing knowledge about skin health, as well as the development of biologics and biosimilars in topical forms have all significantly contributed to the historic period's growth.

What are the Expected Market Size and CAGR for Semi-Solid Dosage Contract Manufacturing by 2029?
In the coming years, a speedy expansion is anticipated in the semi-solid dosage contract manufacturing market, with predictions that it will elevate to $26.76 billion in 2029 with a compound annual growth rate (CAGR) of 10.5%. The significant factors contributing to this growth throughout the projected period consist of the elevated requirements for dermatology therapies, the increasing incidence of chronic skin disorders, the growth in production of generic drugs, the monetary efficiency of contract manufacturing, and an escalation in the need for topical drug delivery. Noteworthy trends during the predicted period encompass progress in formulation technologies, the necessity for adaptable manufacturing capabilities, the application of quality-focused designs, breakthroughs in the technology of semi-solid processing equipment, as well as a surge in the need for expedited drug development.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/semi-solid-dosage-contract-manufacturing-global-market-report

Which Factors Are Driving the Global Semi-Solid Dosage Contract Manufacturing Market Expansion?
A rise in skin disorders is predicted to spur the expansion of the semi-solid dosage contract manufacturing market. Skin disorders refer to conditions that alter the appearance or function of the skin, frequently manifesting symptoms such as irritation, inflammation, or abnormal skin growths. These disorders are increasingly prevalent due to rising environmental pollution, which compromises the skin's defense mechanism, resulting in increased sensitivity, allergic responses, and chronic skin issues. The contract manufacturing of semi-solid dosages aids in skin disease prevention by providing top-quality, accurately formulated topical treatments that efficiently maintain and enhance skin health. For example, Cancer Research UK reported in February 2023 that the average annual incidence of melanoma skin cancer in the UK is expected to climb from approximately 20,800 cases between 2023-2025 to nearly 26,500 cases by 2038-2040. Thus, the high prevalence of skin disorders is propelling the semi-solid dosage contract manufacturing market's growth.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25899&type=smp

Which Segment Currently Holds the Largest Share of the Semi-Solid Dosage Contract Manufacturing Market?
The semi-solid dosage contract manufacturing market covered in this report is segmented -

1) By Type: Topical, Transdermal, Oral
2) By Material Type: Synthetic, Natural, Bio-Based
3) By Company Size: Large Size Companies, Medium And Small Size Companies, Other Company Sizes
4) By Therapeutic Application: Dermatology, Pain Management, Hormonal Therapy, Wound Care, Ophthalmic Disorders, Other Therapeutic Applications
5) By End Use: Pharmaceutical Companies, Cosmeceutical Companies, Other End Uses

Subsegments:
1) By Topical: Creams, Ointments, Gels, Lotions, Pastes, Foams
2) By Transdermal: Transdermal Gels, Transdermal Creams, Transdermal Sprays, Transdermal Emulsions, Medicated Patches
3) By Oral: Oral Gels, Oral Pastes, Oral Suspensions, Oral Emulsions, Oral Jellies

Which Major Trends Are Shaping the Future of the Semi-Solid Dosage Contract Manufacturing Industry?
Key industry players in the semi-solid dosage contract manufacturing market are directing their focus towards strategic investments to trigger innovation and expand into new markets. In the context of businesses, strategic investments are long-term financial decisions made with the intent of bolstering a company's main objectives, promoting future expansion, or securing a strong competitive position in the market. An example is LGM Pharma, an American semi-solid dosage contract manufacturing services provider, which in March 2025 reported an investment of more than $6 million to expand its manufacturing facility in Rosenberg, Texas. This investment is targeted at escalating production capability for various drug formulations such as liquid, suspension, semi-solid, and suppository to cater to the growing domestic pharmaceutical manufacturing demand. It also complements LGM Pharma's continuous growth in prescription drug development, including initiatives like 505(b)(2) and ANDA programs. The enhancements at the Rosenberg location will facilitate increased production while maintaining strict adherence to FDA regulations and up-to-date good manufacturing practices. Operations at the facility will carry on as usual during the process of expansion.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25899&type=smp

Which Key Players Dominate the Semi-Solid Dosage Contract Manufacturing Industry Globally?
Major companies operating in the semi-solid dosage contract manufacturing market are Eurofins Scientific SE, The Lubrizol Corporation, Grunenthal, Recipharm AB, Piramal Pharma Solutions Inc., Cambrex Corporation, Sharp Services, ANI Pharmaceuticals, Pierre Fabre SA, Aurigene Pharmaceutical Services Limited, DPT Laboratories Ltd., Douglas Pharmaceuticals Ltd., Mission Pharmacal Co., Pace Analytical Life Sciences LLC, Bora Pharmaceuticals Co. Ltd., Ascendia Pharmaceuticals Inc., Fermion Oy, Ferndale Pharma Group, Sterling Pharmaceutical Services LLC, Aphena Pharma Solutions Inc., Eubioco LLC, LGM Pharma LLC, Madras Pharmaceuticals, Quality CDMO, Axxelent Pharma Science.

What Are the Fastest-Growing Regions in the Semi-Solid Dosage Contract Manufacturing Market?
North America was the largest region in the semi-solid dosage contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the semi-solid dosage contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.